FDA Approves Tildrakizumab for Psoriatic Arthritis in Adults
Summary
Tildrakizumab is the third IL-23 inhibitor to be approved by the FDA for psoriatic arthritis.
Description from Medscape.
Who is covering this
-
FDA Approves Tildrakizumab for Psoriatic Arthritis in Adults
Tildrakizumab is the third IL-23 inhibitor to be approved by the FDA for psoriatic arthritis.
Related stories
FDA scientists opposed Trump administration’s move to ease peptide access
4 sourcesvia The GuardianTruth score 66
Maharashtra FDA completes proceedings against SRK, Ajay, and Tiger over pan masala ads
3 sourcesvia Times of IndiaTruth score 54
Trump administration says biggest changes coming to infant formula in nearly 30 years
2 sourcesvia ABC News (US)Truth score 532
FDA issues alert about Northfield-based Medline beds tied to fire-related deaths and injuries
2 sourcesvia Chicago Sun-TimesTruth score 52
Maharashtra suspends four FDA officials over hookah tobacco lapses
1 sourcevia India TodayTruth score 40
US FDA approves Inovio's treatment for rare throat disease; shares surge
1 sourcevia ReutersTruth score 47